Skip NavigationSkip to Content
Return Return to Search Results

A novel soluble mimic of the glycolipid, globotriaosyl ceramide inhibits HIV infection

  1. Author:
    Lund, N.
    Branch, D. R.
    Mylvaganam, M.
    Chark, D.
    Ma, X. Z.
    Sakac, D.
    Binnington, B.
    Fantini, J.
    Puri, Z.
    Blumenthal, R.
    Lingwood, C.

  2. Author Address

    Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada. Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada. Canadian Blood Serv, Res & Dev, Toronto, ON M5G 2M1, Canada. Univ Toronto, Dept Med, Toronto, ON, Canada. Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada. Fac Sci & Tech St Jerome, Inst Mediterraneen Rech Nutr, Marseille, France. NCI, Ctr Canc Res, Nanobiol Program, Frederick, MD 21701 USA. Univ Toronto, Dept Biochem, Toronto, ON, Canada.;Branch, DR, Univ Hlth Network, Toronto Gen Res Inst, Div Cell & Mol Biol, 67 Coll St, Toronto, ON M5G 2M1, Canada.;cling@sickkids.ca
    1. Year: 2006
    2. Date: Feb
  2. Journal: Aids
    1. 20
    2. 3
    3. Pages: 333-343
  4. Type of Article: Article
  5. ISSN: 0269-9370
  1. Abstract:

    Objective: To determine the effect of a gp120 binding, non-cytotoxic soluble analogue of the glycosphingolipid (GSL), globotriaosyl ceramide (Gb(3)) on HIV infection in vitro. Design: HIV-1(IIIB) (X4 virus) infection in Jurkat and phytohaemagglutinin (PHAV)/interleukin-2 (IL2) activated, peripheral blood mononuclear cells (PBMC), and HIV-1(Ba-L) (R5 virus) infection of PHA activated PBMC in vitro were assessed. We monitored cell surface markers, cell viability, and viral/host cell morphology to eliminate pleiotropic effects. Viral-host cell fusion was measured to further address any inhibitory mechanism. Methods: HIV infection was monitored by p24(gag) ELISA. CD4, CCR5, CXCR4 and apoptosis were determined by fluorescent antibody cell sorting. A model fusion system comprising a cell line transfected with either CD4 and CXCR4 or CCR5, cocultured with a cell line expressing gp120 from either X4-, R5-tropic HIV-1 or HIV-2 virions, was used. PHA/IL2 activated PBMC GSL synthesis was monitored by metabolic radiolabelling. Results: AdamantylGb(3) blocked X4 and R5 virus infection with a 50% inhibitory concentration of approximately 150 mu M. A reverse transcriptase and a protease-resistant X4 HIV-1 strain retained adamantylGb(3) sensitivity. AdamantylGb3 had minimal effect on cell viability. Treated Jurkat cells showed a small increase in CCR5/CXCR4 expression and a slight, transient CD4 down-regulation, which was probably not related to the mechanism of inhibition. Electron microscopy showed normal viral and host cell morphology following adamantylGb3 treatment, and viral entry was blocked. AdamantylGb(3) was able to prevent virus-host cell fusion irrespective of HIV strain or chemokine receptor preference. Conclusions: These results suggest that adamantylGb3 may provide a new basis for blocking HIV infections, irrespective of HIV envelope/chemokine co-receptor preference or resistance to other therapeutics. (C) 2006 Lippincott Williams & Wilkins.

    See More

  1. Keywords:

External Sources

  1. View record in Web of Science®
  2. WOS: 000235576600004

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel